Major difference between ISR positive cancer news and others
ISR is not in trials, its product is already approved for use, while other stocks with positive cancer news are still in early trials.
IsoRay Skyrockets On New Cesium-131 Brachytherapy Seed Implant Results For Colon Cancer January 21st, 2010 Tags: Brachytherapy seeds, cancer, Cornell, FDA, IsoRay, ISR, New York, picks that move, Weill Cornell Medical Center
IsoRay, Inc. (AMEX:ISR) skyrocketed 110.98% up to $1.730 at midday on news the company announced positive results from the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer which was performed in October 2009 at the Weill Cornell Medical Center in New York. The patient tolerated the implant procedure well, and has had no adverse effects attributed to the use of IsoRay’s proprietary Cs-131 seeds, and no indications the cancer reoccurred. In September IsoRay reported similar positive results for tests of the world’s first Cesium-131 implant for recurrent head and neck cancer. Headquartered in Richland, Washington, IsoRay, Inc. develops, manufactures, and commercializes isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the US and internationally. IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the only producer of the Cesium-131 brachytherapy seed. ISR stock has appreciated 635% since July.